Table 1.
General characteristics of study participants in two study groups.
| Variable | Group | P | |
|---|---|---|---|
| Inulin (n = 30) | Placebo (n = 29) | ||
| Age (year) | 53.63 ± 10.74 | 57.62 ± 12.43 | 0.19 |
| Weight (Kg | 71.00 ± 14.56 | 68.04 ± 15.11 | 0.45 |
| BMI (Kg/m2) | 28.19 ± 5.86 | 27.66 ± 5.26 | 0.72 |
| Waist circumference (cm) | 91.42 ± 10.57 | 95.00 ± 13.40 | 0.26 |
| Female, n (%) | 25 (83.30) | 25 (86.20) | 0.76 |
| Menopause, n (%) | 18 (66.70) | 18 (72.00) | 0.68 |
|
Physical activity levels (MET-minute/week) Low Medium High |
24 (80.00) 4 (13.30) 2 (6.70) |
25 (86.20) 4 (13.80) 0 (0.00) |
0.37 |
|
Socioeconomic status Low Medium High |
8 (26.70) 16 (53.30) 6 (20.00) |
9 (31.00) 8 (27.60) 12 (41.40) |
0.1 |
| Disease duration (year) | 8.70 ± 8.96 | 8.96 ± 8.67 | 0.91 |
|
Medications, n (%) DMARDs and Corticosteroids DMARDs, Corticosteroids, and NSAIDs |
23 (76.70) 7 (23.30) |
21 (72.40) 8 (27.60) |
0.71 |
Data are expressed as mean ± SD or Number (%)—comparison of quantitative and qualitative variables performed by independent samples t-test and Chi-square test respectively.
P < 0.05 was considered statistically significant.
BMI body mass index, MET the metabolic equivalent of the task, DMARDs disease-modifying antirheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs.